WO2015196401A1 - 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用 - Google Patents

癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用 Download PDF

Info

Publication number
WO2015196401A1
WO2015196401A1 PCT/CN2014/080789 CN2014080789W WO2015196401A1 WO 2015196401 A1 WO2015196401 A1 WO 2015196401A1 CN 2014080789 W CN2014080789 W CN 2014080789W WO 2015196401 A1 WO2015196401 A1 WO 2015196401A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
epilepsy
nematode
alzheimer
preventing
Prior art date
Application number
PCT/CN2014/080789
Other languages
English (en)
French (fr)
Inventor
李红玉
王栋
支德娟
李洋
李莹辉
陈晓雨
Original Assignee
兰州大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 兰州大学 filed Critical 兰州大学
Priority to PCT/CN2014/080789 priority Critical patent/WO2015196401A1/zh
Priority to EP14895849.9A priority patent/EP3162377B1/en
Priority to CN201510354410.0A priority patent/CN105194146B/zh
Publication of WO2015196401A1 publication Critical patent/WO2015196401A1/zh
Priority to US15/390,386 priority patent/US10226500B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the invention relates to a new use of epilepsy, in particular to the application of epilepsy in the preparation of a medicament for preventing or treating Alzheimer's disease, and belongs to the field of traditional Chinese medicine.
  • AD Alazheimer's disease
  • MDA receptor N-methyl-D-aspartate
  • ⁇ -amyloid ( ⁇ ) theory The core of this theory is a series of cascade reactions such as free radical reaction, mitochondrial oxidative damage and inflammatory reaction in the abnormal deposition of ⁇ in the brain of patients. Indirect effects on neurons and glial cells ultimately lead to abnormal or death of neurons, causing cognitive impairment and memory loss, ultimately leading to dementia.
  • the senile plaque (SP) formed by the aggregation of ⁇ amyloid ( ⁇ ) in the cerebral cortex and hippocampus of patients with Alzheimer's disease is one of the most important pathological features of Alzheimer's disease, ⁇ - Amyloid protein can effectively weaken synaptic structure and function and is an important substance causing Alzheimer's disease. Therefore, amyloid beta has become a recognized drug target for screening for the prevention or treatment of Alzheimer's disease.
  • Alzheimer's disease The etiology of Alzheimer's disease is complicated and there are many pathogenesis. At present, Western medicine interferes with a specific pathological aspect of Alzheimer's disease and often has drug resistance and serious adverse reactions. Traditional Chinese medicine has a variety of active ingredients and multi-target action characteristics, which makes Chinese medicine have obvious superiority in treating Alzheimer's disease.
  • the epilepsy agent is a tablet, a pill, a capsule, an oral solution or a granule. Different dosage forms do not affect the function of epilepsy in preventing or treating Alzheimer's disease.
  • the epilepsy is used for the preparation of a medicament for preventing or treating Alzheimer's disease, and the epilepsy is an epilepsy tablet.
  • Epilepsy is a proprietary Chinese medicine made from spider scent, scutellaria, uncaria, taurus, ginseng, yarrow, cedar, and menthol. At present, epilepsy is used to affect epilepsy on the wind, or for rickets, insomnia, etc.
  • the invention uses the transgenic C. elegans strain CL4176 as a pathological model for screening for prevention or treatment of Alzheimer's disease drugs to evaluate the effect of epilepsy preventing or treating Alzheimer's disease, based on: cerebral cortex of Alzheimer's disease patients
  • the senile plaque (SP) formed by the aggregation of ⁇ -amyloid ( ⁇ ) in hippocampus is one of the most important pathological features of Alzheimer's disease.
  • ⁇ -amyloid protein can effectively weaken synaptic structure and function, which is caused by Alz. An important substance of Haimo disease.
  • elegans strain CL4176 specifically expresses human ⁇ under the induction of temperature at 25 °C, and ⁇ aggregates in muscle tissue, eventually leading to nematode paralysis.
  • the drug is applied to the nematode strain CL4176, if the nematode population has improved paralysis, the specific manifestation is that the nematode's paralysis time is significantly delayed, indicating that the drug has the effect of preventing or treating Alzheimer's disease.
  • the present invention evaluates the effect of epilepsy on the paralytic phenotype of Caenorhabditis elegans Alzheimer's disease model, and the result confirms that epilepsy is resistant to Caenorhabditis elegans.
  • the paralytic phenotype of the Hammer disease model has a significant inhibitory effect and has the potential to prevent or treat Alzheimer's disease. Therefore, the proprietary Chinese medicine epilepsy tablets can be used for the preparation of a medicament for preventing or treating Alzheimer's disease.
  • Figure 1 shows the effect of the positive drug aqueous solution of memantine hydrochloride on the paralytic phenotype of C. elegans Alzheimer's disease model.
  • Figure 2 shows the effect of aqueous solution of epilepsy on the paralytic phenotype of C. elegans Alzheimer's disease model.
  • BEST MODE FOR CARRYING OUT THE INVENTION The following examples are provided to achieve the use of the epilepsy of the present invention for the preparation of a medicament for preventing or treating Alzheimer's disease, but are not limited to these examples.
  • Example 1 Effect of memantine hydrochloride on Caenorhabditis elegans CL4176 1.
  • Caenorhabditis elegans CL4176 was purchased from Caenorhabditis Genetics Center; for transgenic lines, muscle-specific expression of human ⁇ under the induction of temperature at 25 °C, ⁇ aggregation in muscle tissue, eventually leading to nematode paralysis, this example adopts the nematode strain CL4176 is used as a pathological model for screening drugs for the prevention or treatment of Alzheimer's disease.
  • Escherichia coli ⁇ 50 (uracil leakage mutant), purchased from Caenorhabditis Genetics Center, as a food for C. elegans.
  • Memantine Hydrochloride Chemical Name: 1-Amino-3, 5-Dimethylfunganeamine hydrochloride, Molecular Formula: C 12 H 21 N*HC1, purchased from BEHRINGER Technology, CAS: 41100- 52-1; memantine hydrochloride is a non-competitive MDA receptor antagonist for the treatment of moderate to severe Alzheimer's type dementia. It is reported that memantine (2.16mg/ml) can significantly inhibit the transgenic nematode strain CL4176 paralysis. Phenotype, this example uses it as a positive drug.
  • the solid NGM medium After the solid NGM medium is prepared, it is sterilized at 121 °C for 20 minutes under high pressure. Add 5ml/ml cholesterol 1ml, 1M MgS0 4 lml, 1M CaCl 2 lml under the aseptic table, shake it up, and pour it into the heat. 9 cm culture plate of bacteria, about 20 ml / plate. Allow to stand and wait for the medium to solidify and set aside.
  • Memantine hydrochloride was dissolved in sterile water to prepare a mother liquor of 2.16 mg/ml, and the final concentration of memantine hydrochloride was 215.76 ug/mK 107.88 ug/mK 21.58 ug/mK 4.32 ⁇ g/mK 0.86 ⁇ g/ml.
  • NGM medium The blank control was an NGM medium supplemented with an equal volume of sterile water of memantine hydrochloride under the same conditions.
  • Escherichia coli 0P50 was coated on the above medium as a nematode food.
  • Nematode synchronization Pick NGM medium containing a large number of adult and some nematode eggs have been hatched, The nematode was washed from the medium with M9 solution, transferred to a centrifuge tube, and allowed to stand to allow the nematode to settle freely to the bottom of the tube, and the supernatant was discarded. Add the nematode lysate to the centrifuge tube, and shake it on the vortex mixer for 5-7 minutes to stop vortexing when the nematode is completely broken. Dispense it in a 1.5 mL centrifuge tube and wash the nematode with M9 solution. Egg three times.
  • the L3 stage nematode was transferred to 25 °C for induction, and after 34 hours, the number of nematode paralysis was counted. Count every two hours until all nematodes are paralyzed (paralysis refers to the mechanical stimulation of the nematode body, the nematode can not move or only the head movement), the results are shown in Figure 1.
  • the water-soluble positive drug memantine hydrochloride significantly inhibited the CL4176 paralysis phenotype at 21.58 g/ml, 4.32 g/m 0.86 g/ml, and 215.76 ug/ml of 107.88 g/ml memantine hydrochloride. Strong inhibition of nematode development.
  • the experimental results show that the experimental system is normal, indicating that the present invention can use the C. elegans strain CL4176 as a screening for prevention or treatment of Alzheimer's disease drugs.
  • Epilepsy tablets Manufacturer: Kunming Chinese Medicine Factory, Approval number: National Drug Standard Z53020771 o
  • the epilepsy tablets were ground into powder with a mortar, dissolved in sterile water, and placed into 150 mg/ml epilepsy water solution, sonicated at room temperature for 30 min, centrifuged at 1000 rpm for 10 min, and the supernatant was taken at 4 ° C. save.
  • the aqueous solution of epilepsy tablets was added to the melted NGM medium to prepare NGM medium containing epilepsy tablets with final concentrations of 1. 0 mg/ml, 5. 0 mg/ml, and 15. Omg/ml.
  • the blank control was an NGM medium supplemented with an equal volume of sterile water in the epilepsy water solution under the same conditions.
  • Escherichia coli 0P50 was coated on the above medium as a nematode food.
  • the water-dissolved epilepsy tablets at 15 mg/ml and 5 mg/ml can significantly inhibit the paralysis caused by the overexpression of the transgenic C. elegans ⁇ , especially the 15 mg/ml epileptic tablets, which significantly inhibits ⁇ .
  • the nematode paralysis phenotype ( ⁇ ⁇ 0.001), and each of the above groups showed a certain dose-effect relationship.
  • the epilepsy tablet has a significant inhibitory effect on the paralytic phenotype caused by ⁇ -aggregation of Caenorhabditis elegans in the animal pathological model of Alzheimer's disease, indicating that the epilepsy tablets have prevention or treatment of Al The potential of melanoma.
  • the novel use of the present invention expands the indication of epilepsy and can be used in the preparation of a medicament for preventing or treating Alzheimer's disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用。经实验表明癫痫宁对阿尔茨海默病动物病理模型的麻痹表型具有明显的抑制作用，说明癫痫宁能用于预防或治疗阿尔茨海默病。

Description

癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用 技术领域
本发明涉及癫痫宁的新用途，具体涉及癫痫宁在制备预防或治疗 阿尔茨海默病药物中的应用， 属于中医药领域。
背景技术
阿尔茨海默病 （Alazheimer's disease, AD)是一种以进行性认知 障碍和记忆损伤为主的神经系统退行性疾病。 临床上以记忆障碍、失 语、 失用、 失认、 视空间技能损害、 执行功能障碍以及人格和行为改 变等全面性痴呆表现为特征。目前用于治疗阿尔茨海默病的药物主要 分为两类： 乙酰胆碱酯酶抑制剂 （如加兰他敏） 和 N-甲基 -D-天冬氨 酸受 （ MDA受体） 拮抗剂 （如美金刚）， 但上述药物价格昂贵、 副 作用显著 （幻觉、 意识混沌、 头晕、 头痛和疲倦）， 且只能控制却不 能逆转患者病情。
现代医学对阿尔茨海默病的发病机制进行了多年的研宄，但是由 于其病因复杂， 该病的发病机制至今仍不明确。 目前较为主流的学说 是 β -淀粉样蛋白 （Α β )学说， 该学说的核心是患者大脑中异常沉积 的 Α β通过自由基反应、线粒体氧化损伤和炎症反应等一系列级联反 应， 直接或者间接作用于神经元和神经胶质细胞， 最终导致神经元功 能异常或者死亡， 引发认知损伤及记忆衰退， 最终引起痴呆。
阿尔茨海默病患者的大脑皮层和海马出现 β淀粉样蛋白（Α β )聚 集形成的老年斑 （SP) 是阿尔茨海默病最为主要病理特征之一， β - 淀粉样蛋白可以有效削弱突触结构和功能，是引起阿尔茨海默病的重 要物质。因此 β淀粉样蛋白已成为公认的筛选预防或治疗阿尔茨海默 病药物靶标。
阿尔茨海默病病因复杂且发病环节较多， 目前西药针对阿尔茨海 默病的某一特定病理环节进行干预往往会出现耐药及严重不良反应。 而中药具有多种活性成分、 多靶点的作用特征， 使中药治疗阿尔茨海 默病具有明显的优越性。
发明内容
本发明的目的在于提供癫痫宁的一种新用途，具体涉及癫痫宁在 制备预防或治疗阿尔茨海默病药物中的应用。
所述的癫痫宁药剂为片剂、 丸剂、 胶囊剂、 口服液或颗粒剂。 剂 型不同不影响癫痫宁在预防或治疗阿尔茨海默病方面的功能。
所述的癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用，所 述的癫痫宁为癫痫宁片。
癫痫宁是由蜘蛛香、 石菖蒲、 钩藤、 牵牛子、 千金子、 缬草、 甘 松、 薄荷脑八味药经过现代制药工艺精制而成的中成药。 目前， 癫痫 宁用于风痰上扰癫痫病， 或用于癔病、 失眠等。
本发明将转基因秀丽线虫株系 CL4176作为筛选预防或治疗阿尔 茨海默病药物的病理模型来评价癫痫宁预防或治疗阿尔茨海默病的 作用， 是基于： 阿尔茨海默病患者的大脑皮层和海马出现 β淀粉样蛋 白（Α β )聚集形成的老年斑 （SP) 是阿尔茨海默病最为主要病理特征 之一， β -淀粉样蛋白可以有效削弱突触结构和功能， 是引起阿尔茨 海默病的重要物质。 转基因秀丽线虫品系 CL4176 在 25°C温度诱导 下肌肉特异性表达人类 Α β， Α β在肌肉组织聚集， 最终导致线虫麻 痹。 将药物作用于线虫株系 CL4176, 如果线虫群体麻痹状况得到改 善， 具体表现为线虫的麻痹时间显著延滞， 则说明药物具有预防或治 疗阿尔茨海默病作用。 与现有技术相比， 本发明具有如下有益效果： 本发明评估癫痫宁片对秀丽隐杆线虫阿尔茨海默病模型麻痹表 型的作用，结果证实了癫痫宁片对秀丽隐杆线虫阿尔茨海默病模型麻 痹表型具有明显的抑制作用， 具有预防或治疗阿尔茨海默病的潜力。 因此，中成药癫痫宁片可用于制备预防或治疗阿尔茨海默病的药 物。 附图说明
下面结合附图对本发明的具体实施方式作进一步详细的描述。 图 1 为阳性药物盐酸美金刚的水溶解液对秀丽隐杆线虫阿尔茨 海默病模型麻痹表型的影响。 图 2 为癫痫宁片的水溶解液对秀丽隐杆线虫阿尔茨海默病模型 麻痹表型的影响。 具体实施方式 以下提供具体实施例以实现本发明所述的癫痫宁在制备预防或 治疗阿尔茨海默病药物中的应用， 但不限于这些实施例。 实施例一 盐酸美金刚对秀丽隐杆线虫 CL4176的作用 1.生物材料 ( 1 )秀丽隐杆线虫 CL4176购自 Caenorhabditis Genetics Center; 为转基因品系， 在 25°C温度诱导下肌肉特异性表达人类 Αβ， Αβ在 肌肉组织聚集， 最终导致线虫麻痹， 本实施例采用秀丽线虫品系 CL4176作为筛选预防或治疗阿尔茨海默病症药物的病理模型。
(2) 大肠杆菌 ΟΡ50 (尿嘧啶渗漏突变株）， 购自 Caenorhabditis Genetics Center, 作为秀丽隐杆线虫的食物。
2.试剂
(1) 盐酸美金刚 （MEM)， 化学名称： 1-氨基 -3， 5-二甲基金刚 烷胺盐酸盐， 分子式： C12H21N*HC1， 购自百灵威科技， CAS: 41100-52-1； 盐酸美金刚为非竞争性 MDA受体拮抗剂， 用于治疗 中重度至重度阿尔茨海默型痴呆， 文献报道美金刚 （2.16mg/ml) 能 够显著抑制转基因线虫株系 CL4176麻痹表型， 本实施例将其作为阳 性药物。
(2) 固体 NGM (Nematode Growth Medium) 培养基成分与制作 (以 1升为例）：
Figure imgf000006_0001
固体 NGM培养基配制好后， 121 °C下高压恒温灭菌 20min， 在无菌 操作台下加入 5mg/ml胆固醇 1ml， 1M MgS04 lml, 1M CaCl2 lml，摇匀， 趁热倒入已灭菌的 9cm培养板， 约 20ml/板。 静置等待培养基凝固， 备用。
(3) 配制含盐酸美金刚的 NGM培养基
盐酸美金刚溶解于无菌水中， 配制成为 2.16mg/ml的母液， 分别 配制含盐酸美金刚终浓度为 215.76 u g/mK 107.88 u g/mK 21.58 u g/mK 4.32 μ g/mK 0.86 μ g/ml的 NGM培养基。 空白对照为同样条件下加入与盐酸美金刚等体积无菌水的 NGM培 养基。
上述培养基上均涂布大肠杆菌 0P50作为线虫的食物。
(4) M9液配方
Figure imgf000007_0001
( 5 )裂解液的配制： 6.4% NaC103溶液和 1 M NaOH溶液按体积 比 1 : 1混合。
3. 实施步骤
( 1 ) 线虫的培养： 将线虫接在涂有大肠杆菌 OP50的固体 NGM板上， 然后置于 16 °C的培养箱中培养， 当线虫长到成虫时进行同步化处理。
(2 ) 线虫同步化： 挑选含有大量成虫并且有部分线虫卵已经孵出的 NGM培养基， 用 M9液将线虫从培养基上冲下， 转移到离心管中， 静置使线虫自由 沉降至管底， 弃上清。 视线虫量多少向离心管中加入线虫碱裂解液， 在漩祸搅拌器上振荡 5-7 分钟待线虫全部断裂时停止涡旋,并分装于 1.5mL离心管中， 用 M9溶液洗线虫卵三次。
(3 ) 盐酸美金刚 （MEM) 对秀丽隐杆线虫 CL4176的作用 将同步化后分装于离心管中的线虫卵转移到涂布有 OP50并混合 不同浓度的盐酸美金刚的 NGM培养皿和空白对照为涂布有 OP50并 加有与盐酸美金刚等体积无菌水的 NGM培养皿中， 每个培养皿 60 条线虫， 每个药物浓度三个培养皿作为平行， 16°C培养 3天至 L3期。
为了使线虫表达 A β， 将 L3期线虫转至 25 °C下进行诱导， 34h 后开始计数线虫麻痹条数。每两小时计数一次， 直至所有线虫都麻痹 (麻痹是指机械刺激线虫身体时，线虫不能运动或者只有头部运动）， 结果见图 1。
由图 1可以看出， 水溶解的阳性药物盐酸美金刚在 21.58 g/ml、 4.32 g/m 0.86 g/ml 时能够显著抑制 CL4176 麻痹表型， 215.76 u g/ml 的 107.88 g/ml盐酸美金刚强烈抑制线虫发育。 实验结果表 明本实验体系正常， 说明本发明能够采用秀丽线虫品系 CL4176作为 筛选预防或治疗阿尔茨海默病药物。
实施例二 癫痫宁对秀丽隐杆线虫 CL4176的作用
1.生物材料 同实施例一。
2.试剂
( 1 ) 癫痫宁片： 生产厂家： 昆明中药厂， 批准文号： 国药准字 Z53020771 o
(2 ) 固体 NGM (Nematode Growth Medium) 培养基成分与制作
(以 1升为例）： 同实施例一。
(3) 配制含水溶解的癫痫宁片的 NGM培养基
火焰加热癫痫宁片， 剥去糖衣。 将癫痫宁片用研钵研成粉末， 溶 解于无菌水中， 并配置成为 150mg/ml 癫痫宁片水溶解液， 室温下超 声 30min， 并于 lOOOOrpm下离心 10min， 取上清， 于 4°C保存。 将癫 痫宁片水溶解液加入融化的 NGM培养基中， 配制成为含癫痫宁片终浓 度为 1. 0 mg/ml、 5. 0 mg/ml、 15. Omg/ml的 NGM培养基。
空白对照为同样条件下加入与癫痫宁水溶解液等体积无菌水的 NGM培养基。
上述培养基上均涂布大肠杆菌 0P50作为线虫的食物。
(4) M9液配方: 同实施例一。
( 5 ) 裂解液的配制： 同实施例一。
3. 实施步骤
( 1 ) 线虫的培养： 同实施例一。
(2 ) 线虫同步化： 同实施例一。
(3 ) 癫痫宁片对秀丽隐杆线虫 CL4176的作用 将同步化后分装于离心管中的线虫卵转移到涂布有 OP50并混合 不同浓度的癫痫宁水溶解液的 NGM 培养皿和空白对照为涂布有 OP50并加有与癫痫宁水溶解液等体积无菌水的 NGM培养皿中， 每 个培养皿 60条线虫， 每个药物浓度三个培养皿作为平行， 16°C培养 3天至 L3期。 为了使线虫表达 A β， 将 L3期线虫转在 25 °C下进行诱导， 34h 后开始计数线虫麻痹条数。每两小时计数一次， 直至所有线虫都麻痹 (麻痹是指机械剌激线虫身体时，线虫不能运动或者只有头部运动）， 结果见图 2。
由实验结果可以看出， 水溶解的癫痫宁片在 15mg/ml、 5mg/ml 能显著抑制转基因秀丽线虫 Α β过度表达引起的麻痹， 尤其是 15mg/ml 癫痫宁片极为显著地抑制 Α β引起的线虫麻痹表型 （ρ < 0.001 )， 且上述各组均呈现出一定的量效关系。
总之， 由上述本实施例可以看出， 癫痫宁片对阿尔茨海默病动物 病理模型秀丽隐杆线虫 Α β聚集引起的麻痹表型具有明显的抑制作 用， 说明癫痫宁片具有预防或治疗阿尔茨海默病的潜力。 本发明的新 用途扩大了癫痫宁的适应症，可在制备预防或治疗阿尔茨海默病药物 中应用。

Claims

权利要求书
1. 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用。
2. 根据权利要求 1所述的癫痫宁在制备预防或治疗阿尔茨海默 病药物中的应用， 其特征在于所述的癫痫宁为片剂、 丸剂、 胶囊剂、 口服液或颗粒剂。
3.根据权利要求 2所述的癫痫宁在制备预防或治疗阿尔茨海默病 药物中的应用， 其特征在于所述的癫痫宁为癫痫宁片。
PCT/CN2014/080789 2014-06-26 2014-06-26 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用 WO2015196401A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/CN2014/080789 WO2015196401A1 (zh) 2014-06-26 2014-06-26 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用
EP14895849.9A EP3162377B1 (en) 2014-06-26 2014-06-26 Dianxianning for preventing and treating alzheimer's disease
CN201510354410.0A CN105194146B (zh) 2014-06-26 2015-06-25 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用
US15/390,386 US10226500B2 (en) 2014-06-26 2016-12-23 Use of the Chinese medicine composition and Dianxianning in the preparation of a medicament for preventing or treating Alzheimer's diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/080789 WO2015196401A1 (zh) 2014-06-26 2014-06-26 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/390,386 Continuation-In-Part US10226500B2 (en) 2014-06-26 2016-12-23 Use of the Chinese medicine composition and Dianxianning in the preparation of a medicament for preventing or treating Alzheimer's diseases

Publications (1)

Publication Number Publication Date
WO2015196401A1 true WO2015196401A1 (zh) 2015-12-30

Family

ID=54936468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/080789 WO2015196401A1 (zh) 2014-06-26 2014-06-26 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用

Country Status (3)

Country Link
US (1) US10226500B2 (zh)
EP (1) EP3162377B1 (zh)
WO (1) WO2015196401A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107519323A (zh) * 2017-04-25 2017-12-29 兰州大学 蜘蛛香提取物在制备激活hsp70药物中的应用
CN109223718B (zh) * 2018-10-18 2021-04-20 中国药科大学 细辛脑固体自乳化制剂及其制备方法
CN108938566B (zh) * 2018-10-18 2021-04-20 中国药科大学 细辛脑自乳化系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101732515A (zh) * 2010-01-26 2010-06-16 昆明中药厂有限公司 癫痫宁片的质量检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1084756A (zh) 1993-04-19 1994-04-06 高为人 癫痫宁及其制造方法
CN1054526C (zh) 1996-01-05 2000-07-19 谢志庆 治疗癫痫的中成药
WO2012020423A1 (en) * 2010-08-09 2012-02-16 Interdisciplinary School Of Indian System Of Medicine Role of an herbal formulation in the prevention and management of age related neurodegenerative disorders with special reference to senile dementia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101732515A (zh) * 2010-01-26 2010-06-16 昆明中药厂有限公司 癫痫宁片的质量检测方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI, HAO ET AL.: "Clinical Analysis on Dianxianning Tablet for Refractory Epilepsy", JOURNAL OF MEDICAL FORUM, vol. 25, no. 14, 31 July 2004 (2004-07-31), pages 70, XP008184155 *
See also references of EP3162377A4 *

Also Published As

Publication number Publication date
US10226500B2 (en) 2019-03-12
EP3162377A1 (en) 2017-05-03
EP3162377B1 (en) 2020-08-26
US20170157192A1 (en) 2017-06-08
EP3162377A4 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
Wang et al. Anti-arthritic effect of berberine on adjuvant-induced rheumatoid arthritis in rats
Yan et al. Anthocyanin-rich mulberry fruit improves insulin resistance and protects hepatocytes against oxidative stress during hyperglycemia by regulating AMPK/ACC/mTOR pathway
Parzych et al. An overview of autophagy: morphology, mechanism, and regulation
CN107073123A (zh) 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
Song et al. Cyanidin 3-O-β-glucopyranoside activates peroxisome proliferator-activated receptor-γ and alleviates cognitive impairment in the APPswe/PS1ΔE9 mouse model
Kumar et al. Amelioration of aluminium chloride (AlCl3) induced neurotoxicity by combination of rivastigmine and memantine with artesunate in Albino Wistar rats
WO2015196401A1 (zh) 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用
Liu et al. Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy
Sun et al. Ferulic acid attenuates microglia-mediated neuroinflammation in retinal degeneration
Kahloula et al. Neuro beneficial effects of Pimpinella anisum against lead exposure
Li et al. Current progress on neuroprotection induced by Artemisia, Ginseng, Astragalus, and Ginkgo traditional Chinese medicines for the therapy of Alzheimer’s disease
CN102755341A (zh) 类叶升麻苷在制备防治阿尔茨海默病药物中的用途
JP5856725B2 (ja) うつ病治療用または予防用医薬組成物
CN105311279B (zh) 中药组合物在制备预防或治疗阿尔茨海默病药物中的应用
Abbey et al. Repression of calcitonin gene-related peptide expression in trigeminal neurons by a Theobroma cacao extract
CN105194146A (zh) 癫痫宁在制备预防或治疗阿尔茨海默病药物中的应用
JP6533294B2 (ja) 茯苓皮抽出物を含有する退行性神経疾患の予防、改善または治療用組成物
Zhang et al. Evaluation of structure–activity relationships of ginsenosides against amyloid β induced pathological behaviours in transgenic Caenorhabditis elegans
CN109498703B (zh) 一种党参枸杞组合物在制备治疗阿尔兹海默症药物中的应用
CN109453159B (zh) 一种蜘蛛香提取物单体化合物在制备抗ad药物中的应用
WO2015196402A1 (zh) 中药组合物在制备预防或治疗阿尔茨海默病药物中的应用
Li et al. Control release of α-mangostin by a novel dual-polysaccharides delivery system for colitis treatment under simulated gastrointestinal conditions
Zhang et al. (m) RVD-hemopressin (α) and (m) VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice
Saboo et al. Recent update in management of obesity and overweight patients: standardized extract of Caralluma fimbriata safe and effective therapy
Gorain et al. Mechanistic description of natural herbs in the treatment of dementia: a systematic review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14895849

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014895849

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014895849

Country of ref document: EP